Amylin has lower sales, higher costs as it ramps up Bydureon sales
This article was originally published in Scrip
Executive Summary
Amylin Pharmaceuticals focused on sales of its once-weekly type 2 diabetes drug Bydureon (exenatide) rather than prospective buyers or investor lawsuits during its first quarter 2012 earnings call during which it reported a revenue decline despite its recent product launch. The company attributed the higher net loss to the cost of ramping up sales for Bydureon, which generated $6.9 million in revenue during its first-ever quarter of sales.